The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
about
G-protein-coupled receptors signaling pathways in new antiplatelet drug developmentPharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus.Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridinesPrasugrel hydrochloride for the treatment of sickle cell disease.Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay.Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.Effects of antiplatelet therapy on platelet extracellular vesicle release and procoagulant activity in health and in cardiovascular disease.
P2860
Q26864951-74721A6B-B5CF-415E-9371-F1B04672A4EDQ33685876-EB9123D0-F77C-4C79-9B2F-5B7FF37C4D30Q36974211-0DD6BE75-B100-4315-BE4E-0834CB638F0DQ37540088-5DCCB0E4-CDEC-4E56-B348-7233F5CE11EDQ38106745-70838E8D-127D-46A9-A75D-EF9339D58C62Q38694069-A534139F-2AFB-41A1-A174-AB9A71C63AABQ39340714-CD3BED41-BB18-4E99-AC6D-6F25B65AD80BQ43057004-0D9BBE26-3D2B-4EEE-8101-C13DD52CAFDDQ43288118-30738EBD-4019-4D03-BA8E-0C734AF8344DQ43405386-86023DB7-20A9-4757-ACEA-2460D8FB73F6Q46728729-F733C1B6-1488-458E-A4DE-9F7BDD205F53Q53598292-5A9F79F1-FF0C-4A37-BB78-8148DFB5272F
P2860
The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The active metabolite of prasu ...... flammatory platelet responses.
@en
The active metabolite of prasu ...... flammatory platelet responses.
@nl
type
label
The active metabolite of prasu ...... flammatory platelet responses.
@en
The active metabolite of prasu ...... flammatory platelet responses.
@nl
prefLabel
The active metabolite of prasu ...... flammatory platelet responses.
@en
The active metabolite of prasu ...... flammatory platelet responses.
@nl
P2093
P2860
P1433
P1476
The active metabolite of prasu ...... flammatory platelet responses.
@en
P2093
Atsuhiro Sugidachi
Heather M Judge
Joseph A Jakubowski
Robert J Buckland
P2860
P304
P356
10.1080/09537100701694144
P577
2008-03-01T00:00:00Z